Delcath Systems (NASDAQ:DCTH) Earns Buy Rating from HC Wainwright

Delcath Systems (NASDAQ:DCTH - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $22.00 price objective on the stock. HC Wainwright's target price would indicate a potential upside of 73.36% from the company's previous close.

Several other equities analysts have also recently commented on the stock. Stephens reaffirmed a "buy" rating on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a "sell" rating to a "hold" rating in a report on Friday, October 25th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $21.50.

Delcath Systems Stock Performance

Delcath Systems stock traded down $0.10 during trading on Tuesday, reaching $12.69. 575,136 shares of the company's stock were exchanged, compared to its average volume of 433,555. The company's 50-day moving average is $11.33 and its two-hundred day moving average is $9.83. Delcath Systems has a 52-week low of $3.70 and a 52-week high of $13.30. The firm has a market cap of $405.75 million, a price-to-earnings ratio of -9.40 and a beta of 0.87.

Institutional Investors Weigh In On Delcath Systems

Several institutional investors have recently bought and sold shares of DCTH. Principal Financial Group Inc. acquired a new position in Delcath Systems during the third quarter worth about $808,000. Virtu Financial LLC acquired a new stake in Delcath Systems during the third quarter valued at approximately $289,000. Barclays PLC bought a new stake in Delcath Systems during the third quarter worth approximately $104,000. Geode Capital Management LLC grew its position in Delcath Systems by 3.0% in the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock worth $2,275,000 after buying an additional 7,298 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Delcath Systems during the 3rd quarter valued at $110,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.